Aurinia Pharmaceuticals Inc - Asset Resilience Ratio
Aurinia Pharmaceuticals Inc (AUPH) has an Asset Resilience Ratio of 46.65% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AUPH current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Aurinia Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Aurinia Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Aurinia Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Aurinia Pharmaceuticals Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $337.77 Million | 46.65% |
| Total Liquid Assets | $337.77 Million | 46.65% |
Asset Resilience Insights
- Very High Liquidity: Aurinia Pharmaceuticals Inc maintains exceptional liquid asset reserves at 46.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aurinia Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aurinia Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Aurinia Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Aurinia Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.28% | $317.78 Million | $751.59 Million | -7.67pp |
| 2024-12-31 | 49.95% | $275.04 Million | $550.64 Million | -5.08pp |
| 2023-12-31 | 55.03% | $301.61 Million | $548.06 Million | -7.66pp |
| 2022-12-31 | 62.70% | $295.22 Million | $470.86 Million | +19.60pp |
| 2021-12-31 | 43.10% | $234.18 Million | $543.37 Million | +15.93pp |
| 2020-12-31 | 27.17% | $125.98 Million | $463.66 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $324.30 Million | -- |
| 2018-12-31 | 5.41% | $7.89 Million | $145.86 Million | +1.28pp |
| 2017-12-31 | 4.13% | $7.83 Million | $189.85 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $57.00 Million | -- |
| 2015-12-31 | 29.78% | $10.00 Million | $33.57 Million | +10.69pp |
| 2014-12-31 | 19.09% | $10.00 Million | $52.38 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $23.14 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $4.16 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $14.32 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $10.28 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $9.55 Million | -- |
| 2008-12-31 | 0.00% | $0.00 | $26.66 Million | -- |
| 2007-12-31 | 0.00% | $0.00 | $42.67 Million | -- |
| 2006-12-31 | 28.49% | $8.73 Million | $30.64 Million | -24.46pp |
| 2005-12-31 | 52.95% | $28.78 Million | $54.35 Million | -4.60pp |
| 2004-12-31 | 57.55% | $35.21 Million | $61.17 Million | +10.23pp |
| 2003-12-31 | 47.33% | $35.23 Million | $74.43 Million | +6.02pp |
| 2002-12-31 | 41.30% | $20.93 Million | $50.68 Million | +34.12pp |
| 2001-12-31 | 7.18% | $2.66 Million | $37.06 Million | -39.14pp |
| 2000-12-31 | 46.32% | $6.47 Million | $13.97 Million | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more